Technical Guidance for Research Use of Omeprazole (A2845)

What This Product Solves

Omeprazole, chemically known as 3-(quinolin-4-ylmethylamino)-N-[4-(trifluoromethoxy)phenyl]thiophene-2-carboxamide, serves as a benchmark H+,K+-ATPase inhibitor for research workflows focused on gastric acid secretion mechanisms and antiulcer drug testing. Its well-characterized inhibition of gastric proton pumps makes it essential for modeling gastric acid-related disorders, such as peptic ulcer disease, in preclinical assay systems. This compound is not formulated or validated for any diagnostic, therapeutic, or in vivo clinical application (source: product_spec).

Existing literature and internal guides reinforce that Omeprazole (A2845) is most relevant in workflows requiring a water-insoluble, DMSO-compatible gastric acid secretion inhibitor. For a comprehensive overview of experimental applications and troubleshooting strategies, see the internal article "Omeprazole (A2845): Practical Guide for Gastric Acid Research", which details its role in controlled antiulcer activity studies. Further reference can be made to the article "3-(quinolin-4-ylmethylamino)-N-[4-(trifluoromethoxy)phenyl]thiophene-2-carboxamide" for evidence benchmarks and workflow parameters in gastric acid secretion research.

Protocol Parameters

• assay | IC50 (gastric H+,K+-ATPase inhibition) | 5.8 μM | Suitable for in vitro assessment of proton pump inhibition; use as a reference inhibitor in comparative screens | Numeric value from product_spec (product_spec)
• assay | IC50 (histamine-induced acid formation) | 0.16 μM | Applicable in cell-based or tissue assays modeling histamine-stimulated gastric acid secretion; enables dose-response studies in antiulcer activity research | Numeric value from product_spec (product_spec)
• storage | -20°C (solid), avoid long-term solution storage | Ensures chemical stability and assay reliability for repeated use in gastric acid secretion studies | Product-spec handling guideline (product_spec)
• solvent compatibility | ≥17.27 mg/mL in DMSO; insoluble in water/ethanol | Recommended for stock preparation in DMSO for all antiulcer agent assays; do not attempt aqueous dissolution | Numeric value from product_spec (product_spec)
• working concentration | 0.1–10 μM (typical for in vitro/ex vivo models) | Used in protocol optimization for peptic ulcer disease model and gastric acid-related disorder research | Workflow recommendation (based on internal article synthesis)

Workflow Setup and QC Checklist

For optimal and repeatable results with Omeprazole in gastric acid secretion research or antiulcer activity study protocols, follow these procedural recommendations:

1. Prepare stock solutions in DMSO at concentrations up to the solubility limit (≥17.27 mg/mL). Avoid water or ethanol as solvents due to insolubility (product_spec).
2. Aliquot and store solid Omeprazole at -20°C. Avoid repeated freeze-thaw cycles and long-term storage of DMSO solutions, as stability is reduced in solution form.
3. Use high-purity reagents and freshly prepared working dilutions for each experiment. Target working concentrations in the 0.1–10 μM range, adjusting as required for specific gastric acid or peptic ulcer disease models (workflow recommendation).
4. Include appropriate vehicle controls (DMSO) in all assay plates.
5. Verify compound identity and purity (approx. 98%) upon receipt. Implement a lot-to-lot QC check for new shipments, using HPLC or mass spectrometry as needed.
6. Follow established internal SOPs for dosing, incubation, and endpoint measurement in antiulcer and gastric acid secretion assays.

Common Failure Modes and Fixes

• Precipitation in assay media: If Omeprazole precipitates upon dilution, verify that DMSO concentration does not fall below solubility limits. Prepare concentrated stocks and dilute immediately before use. Do not attempt to dissolve directly in aqueous buffers (product_spec).
• Loss of inhibitory activity: If reduced inhibition is observed, confirm storage temperature and minimize freeze-thaw cycles. Discard aged DMSO solutions and always use freshly prepared aliquots.
• Assay variability: Standardize cell density, incubation times, and compound addition protocols. Employ consistent vehicle control concentrations across all experimental conditions.
• QC discrepancies: For unexpected results or lot-to-lot variation, re-verify compound purity and structure via available analytical methods, and consult product QC documentation.

Scope and Limitations

Omeprazole (A2845) is validated for mechanistic studies in gastric acid secretion and antiulcer agent workflows. It is not suitable for diagnostic procedures, clinical therapeutics, or in vivo human applications. Its application scope is defined by its physicochemical properties: water and ethanol insolubility restricts its use to DMSO-based protocols, and all solution work must be performed promptly to avoid degradation (source: product_spec).

Assay concentration ranges and solvent compatibility should always be determined based on the specific experimental setup. For atomic, workflow-specific recommendations and evidence benchmarks, refer to available internal dossiers such as the 3-(quinolin-4-ylmethylamino)-N-[4-(trifluoromethoxy)phenyl]thiophene-2-carboxamide article.

Conclusion

Omeprazole (A2845) from APExBIO provides a reliable, high-purity H+,K+-ATPase inhibitor for targeted gastric acid secretion and antiulcer activity studies. Adherence to solvent compatibility, storage, and QC protocols is essential for reproducible results. This compound is strictly for research use; any off-label or clinical application is outside validated boundaries. For detailed product specifications and ordering, consult the Omeprazole product page.